Health and Healthcare

Short Sellers Run for Cover From Major Biotechs

Thinkstock

The short interest data are out for the April 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected stocks.

Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 8.85 million shares from the previous level of 9.71 million. Shares closed most recently at $162.85, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had a short interest decrease to 2.12 million shares from the previous level of 2.52 million. Shares closed Tuesday at $281.70, within a 52-week range of $242.07 to $420.99.


Celgene Corp. (NASDAQ: CELG) short interest for this settlement date decreased to 8.46 million shares from the previous 9.99 million. Shares of Celgene closed most recently at $107.55, in a 52-week range of $92.98 to $140.72.

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 26.68 million shares from 29.07 million in the previous period. Shares closed Tuesday at $101.33, in a 52-week trading range of $81.89 to $123.37.

MannKind Corp. (NASDAQ: MNKD) saw its short interest decrease to 103.74 million shares. The previous reading was 112.04 million. Shares closed most recently at $1.62, in a 52-week trading range of $0.64 to $7.32.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.80 million, compared to the previous level of 5.38 million. Shares closed most recently at $154.01, in a 52-week range of $124.16 to $208.88.

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.